Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses.
Adjuvants, Immunologic
/ administration & dosage
Administration, Intranasal
/ methods
Animals
Antigens
/ administration & dosage
Drug Carriers
/ chemistry
Drug Delivery Systems
Female
Immunity, Mucosal
/ immunology
Mice
Mice, Inbred BALB C
Nanoparticles
/ chemistry
Nasal Mucosa
/ immunology
Oils
/ chemistry
Surface-Active Agents
/ chemistry
Vaccination
/ methods
Immunization
Intranasal vaccination
Solid-in-oil nanodispersion
Vaccine
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Dec 2019
15 Dec 2019
Historique:
received:
08
06
2019
revised:
29
09
2019
accepted:
07
10
2019
pubmed:
5
11
2019
medline:
21
4
2020
entrez:
4
11
2019
Statut:
ppublish
Résumé
En masse vaccination is a promising strategy for combatting infectious diseases. Intranasal vaccination is a viable route of mass vaccination, and it could be performed easily via needle-free administration. However, it is not widely used because it tends not to evoke sufficient immunity. The aim of the present study was to improve the performance of intranasal vaccination by extending the amount of time that administered antigens remain in the nasal cavity, and enhancing immune responses via a nanocarrier-based adjuvant. A simple and safe solid-in-oil (S/O) system was investigated as a nanocarrier in intranasal vaccination. S/O nanodispersions are oil-based dispersions of antigens coated with surfactants. Because of the mucoadhesive capacities of surfactant and oil they have high potential to extend the amount of time that administered antigens remain in the nasal cavity, and can induce strong immune responses due to a nanocarrier-based adjuvant effect. In nasal absorption experiments antigens administered intranasally via S/O nanodispersions remained in the nasal cavity longer and induced strong mucosal and systemic immune responses. Histopathology analysis indicated that S/O nanodispersions did not modify the nasal epithelium or cilia, suggesting non-toxicity of the carrier. These results indicate the potential of intranasal vaccination using S/O nanodispersions for future vaccination.
Identifiants
pubmed: 31678377
pii: S0378-5173(19)30822-1
doi: 10.1016/j.ijpharm.2019.118777
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antigens
0
Drug Carriers
0
Oils
0
Surface-Active Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118777Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.